Baxter appeases EU regulators in $4B Gambro buyout
The EU accepts Baxter's concessions over anti-monopoly concerns, allowing the $4B buyout of Swedish dialysis giant Gambro AB to go forward.
After months of negotiations with EuroZone regulators, Baxter's (NYSE:BAX) nearly $4 billion buyout of Swedish dialysis maker Gambro AB can go forward now that Baxter agreed to sell off its renal replacement therapy division to ease anti-trust concerns.
The buyout would give Baxter a strong grasp on the dialysis devices market. Soon after the deal was announced, European regulators threw up a red flag over monopoly concerns, forcing Baxter to propose concessions.